Strides Arcolab has approved merger with Shasun Pharmaceuticals. The combination creates a vertically integrated pharma company of scale with strong presence in Front-ended Regulated Markets Finished Dosages, Emerging Markets Branded Generics, Institutional Business, Active Pharmaceutical Ingredients and Contract Research and Manufacturing Services. Shashun shareholders will receive five equity shares of Strides for every sixteen equity shares held by them in Shasun.
The combination significantly enhances Finished Dosages portfolio in niche and complex domains with a pipeline of over 100 products and accelerates product filings with a combined R&D strength of over 400 personnel. Moreover, the combination creates a top 15 listed Indian pharma company by revenue with increased scale and visibility to drive future growth of the group.
Strides Arcolab is a global pharmaceutical company headquartered in Bangalore, India that develops and manufactures wide range of IP-lead niche pharmaceutical products with an emphasis on sterile injectables.
